Nephrocare Health Services Limited Q3 FY26 results deck summary

Results deck of 10 Feb 2026, summarised by AI from the filing.

Q3 FY26 revenue ₹259.7 cr (+31.7% YoY) and adjusted EBITDA ₹63.1 cr (+43.0% YoY), driven by 17.7% treatment volume growth and higher international mix.

Key takeaways

1. Treatment volumes Treatments increased 17.7% to 9,83,039 in Q3 FY26.
2. Saudi Arabia First dialysis clinic in Riyadh is operations ready, license pending.

Original filing on BSE

Nephrocare Health Services Limited Q1 FY27 results

As filed: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
• Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Nephrocare Health Services Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (12 Aug 2026), Results deck (11 Aug 2026), Results press release (11 Aug 2026)
• Q4 FY26: Earnings call (20 May 2026), Results deck (19 May 2026), Results press release (19 May 2026)
• Q3 FY26: Earnings call (11 Feb 2026), Results deck (10 Feb 2026), Results press release (10 Feb 2026)